PCa is the third most frequently diagnosed cancer among the male European population in 2018.36 The high morbidity constitutes a world‐wide health problem.37, 38, 39, 40 The current detection is based on the determination of prostate specific antigen (PSA) levels in blood, a digital rectal exam, and biopsies.41 However, the varying etiopathology of PCa makes it difficult to define the correct critical limit of PSA‐levels.39 For efficient diagnosis, a PCa‐specific non‐invasive diagnosis supported by medical imaging was urgently needed. The gene discussed is KLK3; the disease is posterior cortical atrophy.